May 13, 2026 EASO Updates Obesity Treatment Algorithm With 2026 Evidence for Weight Loss & Liver Disease
April 25, 2026 Losing Weight Improves Heart Muscle Contraction in Obesity and Heart Failure: New Findings on Severe Obesity and HFpEF Myocardial Dysfunction
April 24, 2026 Study Reveals Stigma Around GLP-1 Weight Loss Drugs: Public Judgment and Social Penalties Rise with Medication Use
April 24, 2026 Key Risk Factors Driving MASLD Across Populations: Insights from Metabolic and Clinical Data
April 24, 2026 How Kelonia Therapeutics Went From Near Bankruptcy to a $3.25B Lilly Acquisition — and What It Means for Biotech M&A and Telehealth Partnerships
April 23, 2026 Genetic Variants Linked to Better Response to GLP-1 Medications for Obesity, Enabling Precision Treatment Approaches
April 23, 2026 Understanding the Link Between Obesity, Diabetes, and Liver Disease: Expert Insights on Prevention, Exercise, and Lifestyle Changes for Better Liver Health
April 22, 2026 Expanding Access to GLP-1s in Medicare and Medicaid: CMS Initiatives, the BALANCE Model, and Implications for Beneficiaries and Budgets
March 31, 2026 Project Remission: New Film Series Highlights Lifestyle Medicine for Type 2 Diabetes Reversal
February 25, 2026 Novo Nordisk’s UBT251: Promising New Weight Loss Drug Shows 20% Weight Loss in Trial
